We spoke to Dr. David Kalfa, pediatric heart surgeon, about a recent breakthrough in the Cardiothoracic Research Lab, the first synthetic patch for heart valve repair that actually mimics the natural valve’s complex structure and function.
We sat down with co-directors of the Aortic Center, Virendra Patel, MD, and Hiroo Takayama, MD, to discuss the exciting new clinical trial for endovascular total aortic arch replacement—a device called the RelayBranch System.
The impact of the results from low-risk TAVR trials will be felt for many years. It will be felt by a wide group - surgeons, cardiologists, hospital systems, insurance companies, and most importantly patients.
While it’s been around for years, TAVR was initially used as a last-chance option for people with highly severe aortic disease who wouldn’t be healthy enough to endure the intensity of a traditional surgery